Journal of Neuro-Oncology

, Volume 135, Issue 1, pp 213–215 | Cite as

Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature

  • Mohamed S. AbdelBaki
  • Steven G. Waguespack
  • Violeta Salceda
  • Jeremy Jones
  • Stacie L. Stapleton
  • David S. Baskin
  • M. Fatih Okcu
Letter to the Editor
  • 126 Downloads

Notes

Funding

There was no funding for this work.

Compliance with ethical standards

Conflict of interest

All the authors declare no conflicts of interest.

Informed consent

Informed consent for treatment with surgery and chemotherapy was obtained from all individual participants included in the study.

Research involving human participants and/or animals

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Heaney AP (2011) Pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 12:3649–3660CrossRefGoogle Scholar
  2. 2.
    Lim S, Shahinian H, Maya M et al (2006) Temozolamide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518–520CrossRefPubMedGoogle Scholar
  3. 3.
    Dworakowska D, Wlodek E, Leontiou CA (2009) Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16:1329–1338CrossRefPubMedGoogle Scholar
  4. 4.
    McCabe CJ, Boelaert K, Tannahill LA (2002) Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238–4244CrossRefPubMedGoogle Scholar
  5. 5.
    Jouanneau E, Wierinckx A, Ducray F (2012) New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 15:37–43CrossRefPubMedGoogle Scholar
  6. 6.
    Oritz LD, Syro LV, Scheithauer BW (2011) Anti-VEGF therapy in pituitary carcinoma. Pituitary 15:445–449CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Mohamed S. AbdelBaki
    • 1
  • Steven G. Waguespack
    • 2
  • Violeta Salceda
    • 3
  • Jeremy Jones
    • 4
  • Stacie L. Stapleton
    • 5
  • David S. Baskin
    • 6
  • M. Fatih Okcu
    • 7
  1. 1.Hematology-Oncology Division, Nationwide Children’s HospitalThe Ohio State UniversityColumbusUSA
  2. 2.Department of Endocrine Neoplasia and Hormonal DisordersUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Hospital Civil de GuadalajaraUniversidad de GuadalajaraGuadalajaraMexico
  4. 4.Division of Diagnostic Radiology, Texas Children’s HospitalBaylor College of MedicineHoustonUSA
  5. 5.Cancer and Blood Disorder InstituteJohns Hopkins All Children’s HospitalSt. PetersburgUSA
  6. 6.Department of Neurosurgery, Houston Methodist HospitalKenneth R. Peak Brain and Pituitary Treatment CenterHoustonUSA
  7. 7.Department of Pediatrics, Hematology-Oncology, Texas Children’s Cancer and Hematology CentersBaylor College of MedicineHoustonUSA

Personalised recommendations